MRI of hip cartilage: joint morphology, structure, and composition.
Stephanie L Gold, Alissa J Burge, Hollis G Potter
https://pubmed.ncbi.nlm.nih.gov/22723242/Actively Recruiting
Led by Cytex Therapeutics, Inc. · Updated on 2026-02-17
15
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a new treatment option for patients aged 14 to 64 years who suffer from hip diseases that cause loss of cartilage integrity on the femoral head, such as femoroacetabular impingement or other structural deformities. These patients have not responded to conservative care and are candidates for surgical intervention. The study focuses on offering an alternative to total hip replacement, which is often unsuitable for younger, active individuals. The investigational treatment is the ReNew Hip Implant, a bioabsorbable, highly porous device designed to mimic healthy cartilage mechanically. This implant combines a biomimetic 3D woven textile with a porous 3D-printed framework and preserves healthy bone stock, allowing for future surgeries if needed. The implant is surgically placed to repair cartilage defects on the femoral head. Participants will be closely monitored through follow-up visits lasting up to five years after surgery. Researchers will assess safety by tracking adverse events and device-related serious adverse events, and effectiveness through pain and function measurements using tools like the international Hip Outcome Tool-33 iHOT-33. Additional evaluations include radiographic imaging, patient-reported outcomes, and health economic measures at various time points up to 60 months.
CONDITIONS
Early Feasibility Study of Cartilage Defect Repair
B
Brad Estes, PhD
C
Christine Estes
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cytex Therapeutics, Inc.
Lead Sponsor
MCRA
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ReNew Hip Implant (Investigational Surgery) | Current Surgical Options (Microfracture / Chondrocyte Implantation) |
|---|---|---|
| What it is | A surgically implanted device made of polycaprolactone biomaterial designed to repair focal cartilage defects in the femoral head of the hip. The implant is tailored to restore joint surface integrity where traditional cartilage is lost. | Current standard options include microfracture surgery, which stimulates repair by creating small holes in the bone, and autologous chondrocyte implantation, where a patient’s own cells are implanted to restore cartilage. Both aim to repair similar focal defects in the hip joint. |
| Role in study | Every participant receives the ReNew Hip Implant for surgical repair. The main study objective is to establish device safety and effectiveness for pain and function after hip cartilage repair. | Microfracture and chondrocyte implantation are typically offered to patients with focal cartilage defects who meet similar eligibility. Treatment assignment depends on defect size, patient factors, and surgeon experience. |
| Primary use | Intended to restore joint surface and reduce pain by repairing localized cartilage loss in the femoral head. Specifically studied for patients not responding to conservative treatment. | Microfracture and autologous chondrocyte implantation are performed to restore cartilage and relieve pain in patients with similar focal defects of the hip. Their aim is to improve function when conservative treatment fails. |
| How it is given or performed | The implant is surgically placed into the femoral head after cartilage defect preparation, using imaging to guide placement and match joint contour. Surgery follows preoperative medical clearance and is performed under anesthesia. | Microfracture involves drilling small holes into the exposed bone to promote cartilage formation. Chondrocyte implantation requires cell harvesting, laboratory preparation, and subsequent surgery to implant the cells into the defect. |
| Evidence status | No published outcome results yet. Effectiveness for pain and function remains under clinical investigation in carefully selected patients. | Microfracture and chondrocyte implantation are supported by published clinical experience and imaging evidence for focal defect repair in the hip. Functional outcomes vary, with some improvement reported, especially in younger patients. |
| Important limitations | Limited to early phase investigation, unknown long-term outcomes, and must match implant to defect accurately. Only carefully selected patients are eligible, and results may not generalize beyond this group. | Outcomes for microfracture and cell implantation can vary depending on age and defect size. Repair may be less durable in larger defects, and repeat procedures may be required. Not every approach is suitable for all patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Hospital admission to discharge
Participants undergo surgery to receive the ReNew Hip Implant and receive immediate post-operative care.
1 surgical visit and hospital stay
Duration - Up to 60 months
Participants are monitored for safety and effectiveness of the implant through regular assessments.
Visits at 6, 12, 24, and 60 months post-surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Stephanie L Gold, Alissa J Burge, Hollis G Potter
https://pubmed.ncbi.nlm.nih.gov/22723242/F W Roemer, D J Hunter, A Winterstein...
https://pubmed.ncbi.nlm.nih.gov/21550411/Cytex Therapeutics, Inc.
Lead Sponsor
MCRA
Collaborating Sponsor